Current trends in the evaluation and management of female urinary incontinence

CMAJ. Canadian Medical Association Journal

Volumn 175, Issue 10, 2006, Pages 1233-1240

  Smith, Phillip P ^a   McCrery, Rebecca J ^a   Appell, Rodney A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIPARKINSON AGENT; ATROPINE; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETHANECHOL; BULKING AGENT; CAPSAICIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; DARIFENACIN; DESMOPRESSIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DIURETIC AGENT; DULOXETINE; ESTROGEN; FLAVOXATE; IMIPRAMINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NARCOTIC AGENT; NEUROLEPTIC AGENT; OXYBUTYNIN; PROPIVERINE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE; UNINDEXED DRUG;

BLADDER DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYSTOSCOPY; DEPRESSION; DIAGNOSTIC PROCEDURE; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG MECHANISM; DRUG TOLERABILITY; EVALUATION RESEARCH; FEMALE; HUMAN; NONHUMAN; PATHOGENESIS; PELVIC FLOOR MUSCLE TRAINING; PRACTICE GUIDELINE; REVIEW; STRESS INCONTINENCE; SURGICAL TECHNIQUE; TREATMENT CONTRAINDICATION; UNSPECIFIED SIDE EFFECT; URGE INCONTINENCE; URODYNAMICS; XEROSTOMIA;

EID: 33751215228     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.060034     Document Type: Review

References (59)

1. Nygaard IE, Heit M. Stress urinary incontinence. Obstet Gynecol 2004;104:607-20.
2. Hu TW, Wagner TH, Bentkover JD, et al. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 2004;63:461-5.
3. Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology 2002;60(suppl):7-12.
4. Serels SR, Appell RA. Contemporary diagnosis and management of bladder control problems. Newtown (PA): Handbooks in Health Care; 2005. p. 14-8.
5. Blaivas JG. Pathophysiology of lower urinary tract dysfunction. Urol Clin North Am 1985;12:215-24.
6. Partoll LM. Voiding dysfunction and retention. In: Walters MD, Karram MM, editors. Urogynecology and reconstructive pelvic surgery. St Louis: Mosby; 1996. p. 329-40.
7. Petros P, Ulmsten U. An integral theory of female urinary incontinence. Experimental and clinical considerations [review]. Acta Obstet Gynecol Scand Suppl 1990;153:7-31.
8. Blaivas JG. The bladder is an unreliable witness. Neurourol Urodyn 1996;15:443-5.
9. Steele AC, Kohli N, Mallipeddi P, et al. Pharmacologic causes of female incontinence. Int Urogynecol J Pelvic Floor Dysfunct 1999;10(2):106-10.
10. Crystle CD, Charme LS, Copeland WE. Q-Tip test in stress urinary incontinence. Obstet Gynecol 1971;38:313-5.
11. Smith PP, Appell RA. Pelvic organ prolapse and the lower urinary tract: the relationship of vaginal prolapse to stress urinary incontinence. Curr Urol Rep 2005;6:340-7.
12. Heesakkers JPFA, Vriesema JLJ. The role of urodynamics in the treatment of lower urinary tract symptoms in women. Curr Opin Urol 2005;15:215-21.
13. Lin LY, Yeh NH, Lin CY, et al. Comparisons of urodynamic characteristics between female patients with overactive bladder and overactive bladder plus stress urinary incontinence. Urology 2004;64:945-9.
14. Digesu GA, Khullar V, Cardozo L, et al. Overactive bladder symptoms: Do we need urodynamics? [published erratum appears in Neurourol Urodyn 2003;22:356]. Neurourol Urodyn 2003;22:105-8.
15. Gupta A, Defreitas G, Lemack GE. The reproducibility of urodynamic findings in healthy female volunteers: results of repeated studies in the same setting and after short-term follow-up. Neurourol Urodyn 2004;23:311-6.
16. Bo K, Talseth T, Holme I. Single blind, randomised controlled trial of pelvic floor exercises, electrical stimulation, vaginal cones, and no treatment in management of genuine stress incontinence in women. BMJ 1999;318:487-93.
17. Neumann PB, Grimmer KA, Grant RE, et al. The costs and benefits of physiotherapy as first-line treatment for female stress urinary incontinence. Aust N Z J Public Health 2005;29:416-21.
18. Hay-Smith J, Herbison P, Ellis G, et al. Which anticholinergic drug for overactive bladder symptoms in adults [review]. Cochrane Database Syst Rev 2005;(3):CD005429.
19. Ghoniem GM, van Leeuwen JS, Elser DM, et al. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol 2005;173:1647-53.
20. Lenzer J. FDA warns that antidepressants may increase suicidality in adults. BMJ 2005;331:70.
21. Chapple CR, Wein AJ, Brubaker L, et al. Stress incontinence injection therapy: what is best for our patients? Eur Urol 2005;48:552-65.
22. Corcos J, Collet JP, Shapiro S, et al. Multicenter randomized clinical trial comparing surgery and collagen injections for treatment of female stress urinary incontinence. Urology 2005;65:898-904.
23. Maher CF, O'Reilly BA, Dwyer PL, et al. Pubovaginal sling versus transurethral Macroplastique for stress urinary incontinence and intrinsic sphincter deficiency: a prospective randomised controlled trial. BJOG 2005;112:797-801.
24. Ulmsten U, Henriksson L, Johnson P, et al. An ambulatory surgical procedure under local anesthesia for treatment of female urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 1996;7:81-5.
25. Jha S, Arunkalaivanan AS, Davis J. Surgical management of stress urinary incontinence: a questionnaire based survey. Eur Urol 2005;47:648-52.
26. Bezerra CA, Bruschini H, Cody DJ. Traditional suburethral sling operations for urinary incontinence in women [review]. Cochrane Database Syst Rev 2005;(3):CD001754.
27. Lapitan MC, Cody DJ, Grant AM. Open retropubic colposuspension for urinary incontinence in women [review]. Cochrane Database Syst Rev 2005;(3):CD002912.
28. Atherton MJ, Stanton SL. The tension-free vaginal tape reviewed: an evidence-based review from inception to current status. BJOG 2005;112:534-46.
29. Dwyer NT, Kreder KJ. An update on slings. Curr Opin Urol 2005;15:244-9.
30. Mellier G, Benayed B, Bretones S, et al. Suburethral tape via the obturator route: is the TOT a simplification of the TVT? Int Urogynecol J Pelvic Floor Dysfunct 2004;15:227-32.
31. De Tayrac R, Deffieux X, Resten A, et al. A transvaginal ultrasound study comparing transobturator tape and tension-free vaginal tape after surgical treatment of female stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2006;17:466-71.
32. Fischer A, Fink T, Zachmann S, et al. Comparison of retropubic and outside-in transoburator sling systems for the cure of female genuine stress urinary incontinence. Eur Urol 2005;48:799-804.
33. Andersson KE, Hedlund P. Pharmacologic perspective on the physiology of the lower urinary tract. Urology 2002;60(5 Suppl 1):13-20.
34. Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003;78:687-95.
35. Hay-Smith EJ, Bo Berghmans LC, Hendriks HJ, et al. Pelvic floor muscle training for urinary incontinence in women [review]. Cochrane Database Syst Rev 2001;(1):CD001407.
36. Dmochowski RR, Davila GW, Zinner NR, et al; Transdermal Oxybutynin Study Group. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002;168:580-6.
37. Davila GW, Daugherty CA, Sanders SW, et al. A short-term multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001;166:140-5.
38. Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003;62:237-42.
39. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. for the STAR study group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70.
40. Kershen RT, Hsieh M. Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine. Curr Urol Rep 2004;5:359-67.
41. Zinner N, Gittleman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004;171:2311-5.
42. Moriya H, Takagi Y, Nakanishi T, et al. Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci 1999;64:2351-8.
43. Yu YF, Nichol MB, Yu AP, et al. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health 2005;8:495-505.
44. Kelleher CJ, Cardozo LD, Khullar V, et al. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br JObstet Gynaecol 1997;104:988-93.
45. Moehrer B, Hextall A, Jackson S. Oestrogens for urinary incontinence in women [review]. Cochrane Database Syst Rev 2003;(2):CD001405.
46. Chapple CR, Parkhouse H, Gardener C, et al. Double-blind, placebo-controlled, cross-over study of flavoxate in the treatment of idiopathic detrusor instability. Br J Urol 1990;66:491-4.
47. Cvetkovic RS, Plosker GL. Desmopressin: in adults with nocturia [published erratum appears in Drugs 2005;65:1072]. Drugs 2005;65:99-107; discussion 108-9.
48. Lose G, Mattiasson A, Walter S, et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol 2004;172:1021-5.
49. Smith CP, Chancellor MB. Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol 2004;171:2128-37.
50. Romito S, Bottanelli M, Pellegrini M, et al. Botulinum toxin for the treatment of genital pain syndromes. Gynecol Obstet Invest 2004;58:164-7.
51. Berghmans LC, Hendriks HJ, De Bie RA, et al.. Conservative treatment of urge urinary incontinence in women: a systematic review of randomized clinical trials. BJU Int 2000;85:254-63.
52. Bo K, Kvarstein B, Nygaard I. Lower urinary tract symptoms and pelvic floor muscle exercise adherence after 15 years. Obstet Gynecol 2005;105:999-1005.
53. Emmons SL, Otto L. Acupuncture for overactive bladder: a randomized controlled trial. Obstet Gynecol 2005;106:138-43.
54. Siegel SW, Catanzaro F, Dijkema HE, et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency and retention. Urology 2000;56:87-91.
55. Schmidt RA, Jonas U, Oleson KA, et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. J Urol 1999;162:352-7.
56. Weil EH, Ruiz-Cerda JL, Eerdmans PH, et al. Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial. Eur Urol 2000;37:161-71.
57. Chaliha C, Khullar V. Mixed incontinence. Urology 2004;63(Suppl 3A):51-7.
58. Dmochowski RR, Staskin D. Mixed incontinence: definitions, outcomes, and interventions. Curr Opin Urol 2005;15:374-9.
59. Paick JS, Ku JH, Shin JW, et al. Tension-free vaginal tape procedure for urinary incontinence with low Valsalva leak point pressure. J Urol 2004;172:1370-3.